Ms. Terrie is a clinical pharmacy writer based in Haymarket, Virginia.
Maraviroc, in combination with other antiretroviral agents, is indicated for treatment-experienced adult patients infected with only chemokine receptor 5 (CCR5)?tropic HIV-1 detectable who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.2 It is classified as a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120.2 The blocking of this interaction prohibits CCR5-tropic entry into cells.1
The agent must be used in conjunction with other antiretroviral agents. According to manufacturer recommendations, the recommended dose of maraviroc varies based on which agent it will be used in conjunction with due to drug interactions (Table).
Maraviroc may be taken without regard to food and is available in 150- and 300-mg tablets. The most common adverse effects associated with the use of maraviroc twice a day include cough, pyrexia, upper respiratory tract infections, rash, musculoskeletal symptoms, abdominal pain, and dizziness.2 Other adverse effects reported with once-aday and twice-daily dosing were diarrhea, edema, influenza, esophageal candidiasis, sleep disorders, rhinitis, parasomnias, and urinary abnormalities.1 Pharmacists should remind patients to immediately seek medical attention if they experience a rash, jaundice, dark urine, vomiting, or abdominal pain. Discontinuation of maraviroc should be considered in any patient showing signs or symptoms of hepatitis, or with increased liver transaminases combined with rash or other systemic symptoms.2
Patients also should be reminded to adhere to the prescribed medication regimen, and if a dose is missed, to take it as soon as possible. If the missed dose is remembered less than 6 hours before the next scheduled dose, however, patients should not take the missed dose, but should wait and take the next scheduled dose. Patients also should be reminded to avoid driving or operating machinery if they experience any episodes of dizziness. Patients also should be advised that the concomitant use of maraviroc and St. John's wort, or products containing St. John's wort, is not recommended. Maraviroc should not be used in individuals younger than 16 years of age and is classified by the FDA as pregnancy category B.2
Raltegravir is an oral agent and the first agent to be approved in a new class of antiretroviral drugs known as integrase inhibitors. Raltegravir exerts its mechanism of action by inhibiting the insertion of HIV DNA into human DNA by the integrase enzyme.3 By inhibiting integrase from performing this essential function, it limits the ability of the virus to replicate and infect new cells.3 While other available agents inhibit 2 other enzymes critical to the HIV replication process—protease and reverse transcriptase—raltegravir is the only drug approved that inhibits the integrase enzyme.3
It is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adults who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is available as 400-mg tablets and is to be administered as 400 mg twice a day without regard to food. Because the safety and efficacy of raltegravir have not been determined, its use is not recommended in treatment-na?ve adult patients or pediatric patients younger than 16 years of age.3 The most common adverse effects reported include nausea, headache, diarrhea, and pyrexia. The plasma concentration of raltegravir may be decreased when given in conjunction with strong inducers of uridine diphosphate glucuronosyltransferase such as rifampin. Raltegravir is classified by the FDA as a pregnancy category C drug. Pharmacists should remind patients that if a dose is missed, it should be taken as soon as possible. If patients do not remember until the time for the next dose, however, patients should be instructed to skip the missed dose and resume the regular schedule. Patients should be reminded to never take 2 tablets at the same time.
Etravirine is an NNRTI of HIV-1 and the first to be approved in over a decade. Etravirine is the first NNRTI to show antiviral activity in treatment-experienced adult patients with HIV resistant to an NNRTI and other antiretroviral agents.4
Etravirine is indicated for use in combination with other antiretroviral agents and is specifically indicated for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral agents.4 It exerts its mechanism of action by binding directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. Etravirine does not inhibit the human DNA polymerases α, β, and γ.4
Etravirine is available in 100-mg tablets, and the recommended initial dosage is 200 mg (100 mg twice a day after a meal). It is classified by the FDA as a pregnancy category B drug. This agent should not be coadministered with the following antiretroviral agents: pranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, full-dose ritonavir (600 mg twice a day), protease inhibitors administered without ritonavir, and other NNRTIs.4 In addition, it should not be coadministered with carbamazepine, phenobarbital, phenytoin, rifampin, rifapentine, rifabutin (when part of a regimen containing protease inhibitor/ritonavir), or products containing St. John's wort.4 More information on potential drug interactions can be found on the product Web site. Patients unable to swallow may disperse the tablet in a glass of water. The most common adverse effects associated with the use of etravirine include rash, diarrhea, nausea, fatigue, abdominal pain, peripheral neuropathy, headache, and hypertension.
* Entry inhibitor—CCR5 coreceptor antagonist.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs